JP2020513014A - ２’−フコシルラクトース化合物による炎症性腸疾患の治療 - Google Patents

２’−フコシルラクトース化合物による炎症性腸疾患の治療 Download PDF

Info

Publication number
JP2020513014A
JP2020513014A JP2019554840A JP2019554840A JP2020513014A JP 2020513014 A JP2020513014 A JP 2020513014A JP 2019554840 A JP2019554840 A JP 2019554840A JP 2019554840 A JP2019554840 A JP 2019554840A JP 2020513014 A JP2020513014 A JP 2020513014A
Authority
JP
Japan
Prior art keywords
fucosyllactose
ibd
subject
day
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513014A5 (https=
Inventor
モロー，アンディス，エル．
デンソン，リー，エー．
ニューバーグ，デービッド，エス．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of JP2020513014A publication Critical patent/JP2020513014A/ja
Publication of JP2020513014A5 publication Critical patent/JP2020513014A5/ja
Priority to JP2023009479A priority Critical patent/JP2023052629A/ja
Priority to JP2024224325A priority patent/JP2025041753A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019554840A 2017-04-07 2018-04-07 ２’−フコシルラクトース化合物による炎症性腸疾患の治療 Pending JP2020513014A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023009479A JP2023052629A (ja) 2017-04-07 2023-01-25 ２’－フコシルラクトース化合物による炎症性腸疾患の治療
JP2024224325A JP2025041753A (ja) 2017-04-07 2024-12-19 ２’－フコシルラクトース化合物による炎症性腸疾患の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482840P 2017-04-07 2017-04-07
US62/482,840 2017-04-07
PCT/US2018/026631 WO2018187792A1 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023009479A Division JP2023052629A (ja) 2017-04-07 2023-01-25 ２’－フコシルラクトース化合物による炎症性腸疾患の治療

Publications (2)

Publication Number Publication Date
JP2020513014A true JP2020513014A (ja) 2020-04-30
JP2020513014A5 JP2020513014A5 (https=) 2021-04-15

Family

ID=63712677

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019554840A Pending JP2020513014A (ja) 2017-04-07 2018-04-07 ２’−フコシルラクトース化合物による炎症性腸疾患の治療
JP2023009479A Pending JP2023052629A (ja) 2017-04-07 2023-01-25 ２’－フコシルラクトース化合物による炎症性腸疾患の治療
JP2024224325A Pending JP2025041753A (ja) 2017-04-07 2024-12-19 ２’－フコシルラクトース化合物による炎症性腸疾患の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023009479A Pending JP2023052629A (ja) 2017-04-07 2023-01-25 ２’－フコシルラクトース化合物による炎症性腸疾患の治療
JP2024224325A Pending JP2025041753A (ja) 2017-04-07 2024-12-19 ２’－フコシルラクトース化合物による炎症性腸疾患の治療

Country Status (8)

Country Link
US (2) US20200129534A1 (https=)
EP (1) EP3606535A4 (https=)
JP (3) JP2020513014A (https=)
CN (1) CN110730665A (https=)
AU (2) AU2018250337B2 (https=)
BR (1) BR112019020911A2 (https=)
CA (1) CA3059265A1 (https=)
WO (1) WO2018187792A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023176950A1 (ja) 2022-03-18 2023-09-21 株式会社明治 腸管内での細菌の増殖制御用組成物及びその利用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021111422A1 (en) * 2019-12-06 2021-06-10 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain
CN111698994A (zh) 2017-11-30 2020-09-22 格礼卡姆股份公司 治疗小麦敏感性的hmo混合物
BE1027078A9 (nl) 2019-02-25 2020-09-28 Nutribam Bvba Samenstelling, voedingssupplement en werkwijze voor het ondersteunen en/of verbeteren van de darmgezondheid
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
EP4058031A4 (en) * 2019-11-14 2023-11-08 Glycom A/S SYNTHETIC COMPOSITION FOR BALANCING THE BALE ACID PROFILE IN THE INTESTINAL
CN111588726A (zh) * 2020-04-28 2020-08-28 南开大学 2′-岩藻糖基乳糖调节宿主肠道菌群及增强肠屏障的应用
CN116615203B (zh) * 2020-12-11 2025-03-07 帝斯曼知识产权资产管理有限公司 改进的益生元制剂
CN113486954B (zh) * 2021-07-06 2023-04-07 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
WO2023102071A1 (en) * 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
CN119842563B (zh) * 2025-03-17 2025-06-06 昆明医科大学第一附属医院(云南省皮肤病医院) 多尔氏菌emf18-06b1d及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120020941A1 (en) * 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
JP2012532195A (ja) * 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
JP2014513697A (ja) * 2011-05-13 2014-06-05 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
JP2015512936A (ja) * 2012-04-13 2015-04-30 トラスティーズ オブ ボストン カレッジ プレバイオティクス組成物およびその使用方法
JP2015524558A (ja) * 2012-07-20 2015-08-24 ネステク ソシエテ アノニム 腸管免疫に関するバイオマーカーとしてのフコース
WO2016066174A1 (en) * 2014-10-29 2016-05-06 Glycom A/S Synthetic composition and method for promoting mucosal healing
WO2016116580A1 (en) * 2015-01-23 2016-07-28 Nestec S.A. Nutritional composition useful in the treatment of ibd patients
WO2016122889A1 (en) * 2015-01-26 2016-08-04 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009315A2 (en) * 2010-07-12 2012-01-19 The Regents Of The University Of California Bovine milk oligosaccharides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532195A (ja) * 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
US20120020941A1 (en) * 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
JP2014513697A (ja) * 2011-05-13 2014-06-05 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
JP2015512936A (ja) * 2012-04-13 2015-04-30 トラスティーズ オブ ボストン カレッジ プレバイオティクス組成物およびその使用方法
JP2015524558A (ja) * 2012-07-20 2015-08-24 ネステク ソシエテ アノニム 腸管免疫に関するバイオマーカーとしてのフコース
WO2016066174A1 (en) * 2014-10-29 2016-05-06 Glycom A/S Synthetic composition and method for promoting mucosal healing
WO2016116580A1 (en) * 2015-01-23 2016-07-28 Nestec S.A. Nutritional composition useful in the treatment of ibd patients
WO2016122889A1 (en) * 2015-01-26 2016-08-04 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023176950A1 (ja) 2022-03-18 2023-09-21 株式会社明治 腸管内での細菌の増殖制御用組成物及びその利用

Also Published As

Publication number Publication date
US20200129534A1 (en) 2020-04-30
CA3059265A1 (en) 2018-10-11
EP3606535A1 (en) 2020-02-12
US20220133758A1 (en) 2022-05-05
BR112019020911A2 (pt) 2020-05-12
EP3606535A4 (en) 2020-12-16
AU2024203194A1 (en) 2024-05-30
AU2018250337B2 (en) 2024-02-15
WO2018187792A1 (en) 2018-10-11
JP2025041753A (ja) 2025-03-26
JP2023052629A (ja) 2023-04-11
AU2018250337A1 (en) 2019-10-24
CN110730665A (zh) 2020-01-24

Similar Documents

Publication Publication Date Title
JP2025041753A (ja) ２’－フコシルラクトース化合物による炎症性腸疾患の治療
Caenepeel et al. how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease
Suskind et al. Clinical and fecal microbial changes with diet therapy in active inflammatory bowel disease
Sood et al. Diet and inflammatory bowel disease: The Asian Working Group guidelines
Patrone et al. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement
Candela et al. Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-Pi 2 diet
Verburgt et al. Successful dietary therapy in paediatric Crohn’s disease is associated with shifts in bacterial dysbiosis and inflammatory metabotype towards healthy controls
US9386793B2 (en) Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
Zhang et al. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial
JP2020532515A (ja) マイクロバイオーム関連障害の処置のための方法および組成物
Franzin et al. Microbiota and drug response in inflammatory bowel disease
Taguer et al. The complex interplay of diet, xenobiotics, and microbial metabolism in the gut: Implications for clinical outcomes
Yan et al. Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
Bertin et al. Diet and gut microbiota in inflammatory bowel disease: a clinical and nutritional perspective
Ward et al. Effects of fermented and fiber-rich foods on maternal & offspring microbiome study (FeFiFo-MOMS)—study design and methods
Szymańska et al. Pediatric patient with hyperketotic hypoglycemia diagnosed with glycogen synthase deficiency due to the novel homozygous mutation in GYS2
Stevenson et al. Probiotic effect and dietary correlations on faecal microbiota profiles in irritable bowel syndrome
Nikoonezhad et al. Comparison of oral zinc supplement and placebo effect in improving the T-cells regeneration in patients undergoing autologous hematopoietic stem cell transplantation: Clinical trial study
BR122024023543A2 (pt) Composição farmacêutica, kit e usos de compostos 2'-fucosilactose no tratamento de doenças inflamatórias intestinais
Heenan The colonic luminal microenvironment and symptoms of irritable bowel syndrome
Valerio Efficacy of the Autoimmune Protocol Diet for the Treatment of Adult Patients with Mild to Moderate Crohn's Disease
Wang The effect of combinatory dietary fibers on the gut microbiota and human gastrointestinal health
Haddadi et al. Signs, symptoms and complications of non-Hodgkin's lymphoma according to grade and stage in south Iran
Yusuf et al. An Emerging Approach to IBD Treatment: Personalized Nutrition Through Gut Microbiome Optimization
Blee Assessing the role of dietary interventions on the gut microbiome: a potential therapeutic for IBD

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230125

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230125

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230207

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230314

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230320

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241126